Rotenone is a naturally occurring
toxin that inhibits complex I
of the mitochondrial electron transport chain. Several epidemiological
studies have shown an increased risk of Parkinson’s disease
(PD) in individuals exposed chronically to rotenone, and it has received great attention for
its ability to reproduce many critical features of PD in animal models.
Laboratory studies of rotenone have repeatedly shown that it induces
in vivo substantia nigra dopaminergic cell loss, a hallmark of PD
neuropathology. Additionally, rotenone induces in vivo aggregation
of α-synuclein, the major component of Lewy bodies and Lewy
neurites found in the brain of PD patients and another hallmark of
PD neuropathology. Some in vivo rotenone models also reproduce peripheral
signs of PD, such as reduced intestinal motility and peripheral α-synuclein
aggregation, both of which are thought to precede classical signs
of PD in humans, such as cogwheel rigidity, bradykinesia, and resting
tremor. Nevertheless, variability has been noted in cohorts of animals
exposed to the same rotenone exposure regimen and also between cohorts
exposed to similar doses of rotenone. Low doses, administered chronically,
may reproduce PD symptoms and neuropathology more faithfully than
excessively high doses, but overlap between toxicity and parkinsonian
motor phenotypes makes it difficult to separate if behavior is examined
in isolation. Rotenone degrades when exposed to light or water, and
choice of vehicle may affect outcome. Rotenone is metabolized extensively
in vivo, and choice of route of exposure influences greatly the dose
used. However, male rodents may be capable of greater metabolism of
rotenone, which could therefore reduce their total body exposure when
compared with female rodents. The pharmacokinetics of rotenone has
been studied extensively, over many decades. Here, we review these
pharmacokinetics and models of PD using this important piscicide.